Diabetic patients taking Invokana, Farxiga, or Jardiance are on alert over reports that these SGLT2 inhibitors could possibly cause a potentially lethal flesh-eating infection of the genitals. Bloomberg recently reported that SGLT2 inhibitor-induced Fourneir’s gangrene was observed in a dozen patients between March 2013 and May 2018. All cases required surgery and in one case the condition proved fatal. The FDA has said that more ...
Diabetes Drug Linked to Flesh-Eating Genital Infection
Posted September 25, 2018 in Drug and Medical Device Lawsuits | Product News and Recalls
Patients taking Invokana and other SGLT2 inhibitors to treat and control their Type II diabetes have done so with the risk of a wide variety of adverse side effects for quite some time. The drugs’ links to serious conditions like bone fractures, kidney failure, and a particularly dangerous condition known as ketoacidosis are well established. They can strike anyone – young, old, men, and women.
However, there is read more.... --> continue reading...
Known as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.
Unfortunately, this relatively new class of drugs has already allegedly caused enough ...
continue reading...Lopez McHugh Files Invokana Lawsuit Alleging Diabetic Ketoacidosis Injury
Posted December 11, 2015 in Drug and Medical Device Lawsuits | Product News and Recalls
PHILADELPHIA (December 2015) – The national trial lawyers of Lopez McHugh have filed a lawsuit against Johnson & Johnson and its subsidiary, Janssen, alleging that its diabetes medication, Invokana®, causes patients to develop diabetic ketoacidosis.
The lawsuit (Case No. 15-12-00653) was filed in the Court of Common Pleas, Philadelphia County, and includes allegations that the manufacturers of Invokana knew that the drug could cause diabetic ketoacidosis but failed to warn doctors.
Diabetic ketoacidosis is a condition where the body produces ketones, ...
continue reading...Invokana Maker Counters with Own SGLT2 Inhibitor Study
Posted August 20, 2015 in Product News and Recalls
Amid recent research linking sodium-glucose cotransporter-2 (SGLT2) inhibitors to diabetic ketoacidosis, Invokana maker Janssen Pharmaceutica has countered with its own report on the new diabetic drug. The study, published in late July by the journal Diabetes Care, claims that incidents of the potentially fatal blood condition are “rare.”
SGLT2 inhibitors are a relatively new class of type 2 diabetes drugs. They work by reducing the amount of glucose reabsorbed in the ...
continue reading...Endocrinologists to Explore Link between SGLT2 Inhibitors and Diabetic Ketoacidosis
Posted August 4, 2015 in Product News and Recalls
The American Association of Clinical Endocrinologists (AACE) has begun looking into the possible link between sodium-glucose cotransporter-2 (SGLT2) inhibitors, an emerging class of diabetes drugs, and the severe blood condition known as diabetic ketoacidosis. According to Diabetes.co.uk, the AACE plans to hold a conference on the subject in late October.
SGLT2 inhibitors are a new type of diabetes medication approved by the U.S. Food and Drug Administration (FDA) ...
continue reading...
